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Abstract
In this paper we discuss five different corpora annotated for protein names. We present several within- and cross-dataset protein tagging
experiments showing that different annotation schemes severely affect the portability of statistical protein taggers. By means of a detailed
error analysis we identify crucial annotation issues that future annotation projects should take into careful consideration.
1. Introduction
The huge and constantly increasing amount of electroni-
cally available papers in the biomedical domain has trig-
gered a high volume of research on automatically extracting
biomedical information from the literature. A primary step
in information extraction is recognising entities of interest,
such as proteins, genes, cell lines, and so on, for which
relevant information can then be extracted. Machine learn-
ing approaches currently dominate the eld, and in order
to train statistical models several text collections have been
annotated with these entities. The attractiveness of learning
methods is their portability and reusability: given the same
entity types and similar text types, one should, for example,
be able to use a protein name model trained on one corpus
to recognise proteins in a new one.
However, different annotation projects employ different
denitions of what constitutes an entity. As a consequence,
what is marked as a protein in one text collection might not
be marked as one in another, or their boundaries might not
coincide. In this paper, we present a survey of different cor-
pora and annotation schemes for protein markup and show
that they differ substantially. The biomedical corpora which
we examine are described in Section 2. By means of sev-
eral within- and cross-dataset protein tagging experiments
on such corpora, described in Section 3, we show that this
lack of annotation standards constitutes a major shortcom-
ing in the portability and reusability of trained models and
their evaluation. We also present examples of different er-
ror types. In Section 4, we provide an overview of within-
and cross-dataset inconsistencies in the annotation.
2. Biomedical Datasets and Preprocessing
With more and more biomedical datasets becoming pub-
licly available, there has been some research effort on cor-
pus design issues and usage in biomedical natural language
processing (Cohen et al., 2005a; Cohen et al., 2005b). It
is suggested that the usability and usefulness of a corpus
is largely dependent on the annotation format and the pro-
vision of high quality markup of structural and linguistic
characteristics of its content. In this paper, we look at the
actual entity annotation variation within and across differ-
ent collections and argue for standardised annotation guide-
lines for biomedical named entities.
We discuss experiments involving ve different biomedi-
cal datasets, namely the BioNLP Coling 2004 corpus (Col-
lier et al., 2004), the Texas UTML corpus (Bunescu et al.,
2005), the PIR Georgetown corpus (Mani et al., 2005), the
Yapex corpus (Franz·en et al., 2002) and the Bio1 corpus
(Tateisi et al., 2000). All ve datasets are composed of
(sentences from) Medline abstracts and contain manually
annotated protein names.
We also examined the BioCreative data (Hirschman et al.,
2004) and the oncology data of PennBioIE version 0.9
(Bies et al., 2005). The BioCreative corpus is made up of
sentences selected from Medline abstracts. 50% of them
were taken from abstracts similar to documents with known
gene or protein names. The other 50% stem from ab-
stracts unlikely to contain such names. In this dataset,
protein names are not differentiated from gene names and
are assigned the same entity tag. The PennBioIE oncology
dataset contains Medline abstracts on the molecular genet-
ics of cancer. This dataset differentiates between the enti-
ties Gene-RNA (genes and RNA elements), Gene-protein
(non-genomic downstream products of genes and RNA el-
ements) and Gene-generic (if unclear or ambiguous). Be-
cause we are interested in protein tagging as distinguished
from gene tagging, we omit these two corpora from the ex-
periments and discussion presented in this paper.
As the original markup of all datasets differs, we converted
it into a common standard XML representation. We then
tokenised all datasets with the same rule-based grammar
which splits text into tokens surrounded by white space
and punctuation, with further splits at certain hyphens and
slashes.1 The tokenisation grammar was applied using re-
cently improved upgrades of the XML tools described in
(Thompson et al., 1997) and (Grover et al., 2000).2 Each
1The BioNLP dataset was released pretokenised with splits oc-
curring at whitespace and sentence punctuation. We used this to-
kenisation as input into our tokeniser which is more fine-grained.
2These tools will soon be available under GPL as LT-XML2
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Corpus Total Size Size of Training Set Size of Test Set Entity Markup Reference
BioNLP 650,720 tokens 540,269 tokens 110,451 tokens protein (plus DNA,
RNA, cell line and
cell type)
Collier et al. (2004)
Texas 206,209 tokens - - protein Bunescu et al. (2005)
PIR 77,528 tokens - - protein Mani et al. (2005)
Yapex 55,616 tokens 28,201 tokens 27,415 tokens protein Franz·en et al. (2002)
Bio1 27,476 tokens - - protein (plus DNA,
RNA, cell line, cell
type, mono-organism,
multi-celled
organism, virus,
sublocation and tissue
Tateisi et al. (2000)
Table 1: Description of different biomedical datasets.
tokenised dataset was subsequently assigned part-of-speech
(POS) tags using a Maximum Entropy POS tagger (Cur-
ran and Clark, 2003a) trained on the Medpost training data
(Smith et al., 2004).
All ve corpora which we examined contain documents in
the domain of biomedicine, but some of them vary with re-
gard to their type of topic restriction of this broad area. As
can be seen in Table 1, the collections also vary in size.
The BioNLP corpus is the largest dataset containing 2000
Medline abstracts from the Genia version 3.02 corpus (Ohta
et al., 2002). This corpus was constructed by querying
Pubmed with the search terms human, transcription fac-
tor and blood cell. The BioNLP corpus is marked up for 5
entity classes: protein name, DNA, RNA cell line and cell
type. We retained only the protein markup for comparison
with other datasets. The BioNLP data is split into a training
and a test set. The Texas and the PIR datasets are smaller
collections. The former is made up of a total of 750 Med-
line abstracts containing the word human. The latter is a
collection of 300 Medline abstracts selected from curated
PIR-NREF (Non-Redundant REFerence protein) database
entries with no restriction in query. As both the Texas and
the PIR datasets contain embedded entities, we trained and
tested the tagger on the outermost annotations for such in-
stances. The PIR corpus was annotated following speci-
cally developed guidelines that have also been made pub-
licly available (PIR, 2004). Yapex is one of the smaller cor-
pora with only 200 Medline abstracts manually tagged for
protein names. 147 of these abstracts were randomly cho-
sen from a set of Medline abstracts containing the MeSH
terms protein binding, interaction and molecular. These
make up all of the training and approximately half of the
test set. The remaining abstracts in the test set were ran-
domly selected from the Genia corpus (Ohta et al., 2002).
Finally, the Bio1 corpus is made up of a random selection of
100 Medline abstracts retrieved from PubMed by querying
for human, blood cell and transcription factor. Its content
is therefore similar to that of the BioNLP corpus which was
collected on the basis of the same search terms. The Bio1
corpus was manually annotated by domain experts for pro-
tein names as well as a series of other entities (see Table 1).
and LT-TTT2 at: http://www.ltg.ed.ac.uk
3. Protein Tagging Experiments
The experiments we present in this section are designed as
follows: we train a Maximum Entropy tagger (Curran and
Clark, 2003b) on a portion of a given dataset and then test
it on a portion of the same collection (within-dataset) as
well as on a different collection (cross-dataset). We use the
standard feature set implemented in the tagger, namely pre-
x and sufx information, morphological and orthographic
characteristics, word length, word type, POS tags of cur-
rent and two previous words as well as context named en-
tity (NE) tags and memory NE tag. The latter is the NE
tag that was most recently assigned to the current word.
We did not attempt to optimise feature settings for protein
name recognition as our aim was not to achieve the best
named entity recognition (NER) performance but rather to
compare results across different datasets in relation to each
other. We show that testing the model on a different corpus
yields a severe drop in performance when compared to test-
ing on the same set, and, most importantly, that such a fall
is mainly due to discrepancies in the annotation.
3.1. Results
We rstly determine how well the NE tagger is able to
recognise protein names in the various within-dataset ex-
periments, i.e. when the training data stems from the same
collection as the test data (Table 2). While we use the
training and test sets distributed as part of the BioNLP
and the Yapex collections for these experiments, we per-
form 10-fold cross-validation on the Texas, the PIR and the
Bio1 corpora. Table 2 shows, for example, that the tagger
yields a relatively high precision, recall and F-score when
trained and tested on the Bio1 dataset, showing that larger
Within-dataset experiments
Training Set Test Set Precision Recall F-Score
BioNLP BioNLP 64.20% 66.33% 65.25
Texas Texas 68.84% 46.08% 55.20
PIR PIR 70.23% 64.37% 67.17
Yapex Yapex 74.63% 43.69% 55.12
Bio1 Bio1 75.97% 65.74% 70.48
Table 2: Protein name recognition results for within dataset
experiments.
596
sized training sets do not necessarily guarantee the high-
est scores. The lower scores of the models trained on the
Texas and Yapex datasets also indicate that these collec-
tions are likely to contain more internal inconsistencies in
their annotation. Interestingly, their low F-scores are due
to the low recall scores rather than their precision scores
which are comparable with those of the other experiments.
The Texas and Yapex models essentially miss many protein
names in the test data. We suspect that this could be partly
the effect of the inconsistencies in the training data leading
the tagger to uncertainty when making a hypothesis. This
means that when the tagger is provided with noisy training
material, it does not assign the protein tag unless it is fairly
condent.
We compare all results from the within-dataset experi-
ments to those of several cross-dataset experiments with the
BioNLP data as the test set and the four other datasets as
training sets. Each model performs considerably less well
on the BioNLP test data than on data from its own collec-
tion (see Table 3).
Cross-dataset experiments
Training Set Test Set Precision Recall F-Score
Texas BioNLP 44.05% 24.24% 31.27
PIR BioNLP 39.81% 42.91% 41.30
Yapex BioNLP 36.69% 24.29% 29.23
Bio1 BioNLP 46.14% 44.35% 45.22
Table 3: Protein name recognition results for cross-dataset
experiments.
However, a number of errors in the cross-dataset experi-
ments are obviously due to unseen tokens in the test data.
We therefore ran within- and cross-dataset experiments
where all the word features were ignored: the tagger merely
relies on word-internal and -external context features but
not the identity of the words themselves and is therefore
prevented from learning a lexicon of protein names con-
tained in the training data (see Table 4). These are fairer
gures for comparing results, as the tagger cannot rely on
lexical information from the training set.
Within-dataset experiments (no word-features)
Training Set Test Set Precision Recall F-Score
BioNLP BioNLP 55.27% 30.22% 39.07
Texas Texas 61.01% 37.18% 46.20
PIR PIR 63.24% 57.13% 60.03
Yapex Yapex 64.65% 42.32% 51.15
Bio1 Bio1 69.32% 59.44% 64.00
Table 4: Protein name recognition results for within dataset
experiments when ignoring word features.
As Table 5 shows, testing models trained on the Texas, PIR,
Yapex and Bio1 data on the BioNLP test data still yields
a serious performance fall. Comparing, for example, the
results of the Bio1 model in the within- and cross-dataset
experiments shows a drop of over 25 points: from 64.00
(training/testing on Bio1) to 38.34 points (testing the Bio1
model on BioNLP). The other models show a similar
tendency when tested on the BioNLP data. The average
Cross-dataset experiments (no word-features)
Training Set Test Set Precision Recall F-Score
Texas BioNLP 39.15% 18.59% 25.21
PIR BioNLP 34.65% 35.98% 35.30
Yapex BioNLP 31.50% 24.67% 27.67
Bio1 BioNLP 40.69% 36.25% 38.34
Table 5: Protein name recognition results for cross-dataset
experiments when ignoring word features.
performance drop of all models is 23.7 points.
As could have been anticipated from the previous results,
Table 6 shows that combining the different collections
for training a model does not lead to better perfomance.
When adding the Texas, Yapex and Bio1 datasets to the
BioNLP training data, performance actually decreases to
63.58, 64.37 and 64.76 points F-score respectively, com-
pared to when training solely on the BioNLP data, which
results in an F-score of 65.25. Adding the PIR data to the
BioNLP training data yields a small but negligible improve-
ment. This shows that increasing the amount training data
is not useful unless it is consistent.
Combined-dataset experiments
Training Set Test Set Precision Recall F-Score
BioNLP+Texas BioNLP 63.22% 63.94% 63.58
BioNLP+PIR BioNLP 63.38% 67.34% 65.30
BioNLP+Yapex BioNLP 65.04% 63.73% 64.37
BioNLP+Bio1 BioNLP 64.91% 64.61% 64.76
Table 6: Protein name recognition results for combined-
dataset experiments.
The results of all our experiments illustrate that while a
model trained on a specic corpus may perform relatively
well on data from the same collection, it may not do so on a
new corpus in the same domain. One reason for this dicrep-
ancy in performance are tagging errors caused by annota-
tion inconsistencies across datasets. In the remaining part
of the paper, we will present examples of different types of
NER errors and examine annotation inconsistencies within
and across each of the biomedical datasets.
3.2. Error Analysis
A detailed error analysis of output obtained from cross-
dataset experiments illustrates that despite missing protein
names as a result of the differences in sub-domain, many
tagging errors could have been avoided if the annotation
of the different datasets was consistent. For example, we
observe many left and right boundary errors, as in the fol-
lowing two examples which occur when testing the Texas
and the Bio1 models, respectively, on the BioNLP data:
(1) GOLD:   prot  NF-kappa B complexes   /prot 
TAGGED:   prot  NF-kappa B   /prot  complexes
(2) GOLD:   prot  human STAT6   /prot 
TAGGED: human   prot  STAT6   /prot 
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There are also errors in the tagging of coordinated NPs as
well as abbreviations. The following two extracts are exam-
ples of such errors that occurred in the output of the Yapex
and the PIR model:
(3) GOLD:   prot  HSV-1 ICP0 and CMV IE1
proteins   /prot 
TAGGED: HSV-1   prot  ICP0   /prot  and
  prot  CMV IE1   /prot  proteins
(4) GOLD:   prot  interleukin 2 (IL 2)   /prot 
TAGGED:   prot  interleukin 2   /prot 
(   prot  IL 2   /prot  )
Moreover, there are more false negatives in the case of gen-
eral protein names (annotated in the BioNLP gold standard)
if they were not annotated in the training dataset, as for ex-
ample in the Texas data:
(5) GOLD: predominant   prot  cellular
proteins   /prot 
TAGGED: predominant cellular proteins
These are a selection of error types caused by annotation
inconsistencies across datasets which are investigated in the
following section.
4. Annotation Inconsistencies
Error analysis showed that inconsistencies in the annota-
tion of protein names across datasets are a main cause of
NER errors in the cross-dataset experiments. In this sec-
tion, we present different types of inconsistencies which
exist not only across but also within datasets. We mainly
focus on protein name boundaries, coordination, abbrevia-
tions as well as general protein names and provide relevant
examples.3
4.1. Protein Name Boundaries
Boundary inconsistencies of entities are one major differ-
ence in the annotation across datasets. For example, the
word protein following a protein name (i.e. X protein) is
always annotated as part of the entity in the PIR and Bio1
datasets.4 Similarly, it tends to be included, although not
consistently, in the annotation of the BioNLP dataset (in
90.5% of cases). Both the Texas and Yapex datasets in
turn contain some annotations where the word protein is
included (47.4% and 62.7%, respectively) and some where
it is not (52.6% and 37.3%, respectively) and therefore
present very contradictory information to the learner. The
Texas and Yapex datasets show a more consistent treatment
of the word complex, which is never included in the an-
notation at the end of a protein name. However, the word
complex in that same position is always annotated in the
PIR data and in 96.4% of cases in the BioNLP data. In
the BioNLP data, for example, the string AP-1 complex is
in all but one cases annotated as a full protein name. The
3The examples given in this section contain a common XML
markup and not the original markup convention of each dataset.
4We do not distinguish between protein names ending in the
word protein and those that are modified by the word protein.
Bio1 dataset only contains very few protein names followed
by the word complex, which is either included (72%) or not
(28%). One type of entity where the annotations are consis-
tent across datasets at least in the majority of cases is when
a protein name ends in the word receptor which is gener-
ally considered part of the named entity. However, only the
PIR and Bio1 datasets are completely consistent in their
markup. All other datasets also contain annotations where
the entity does not span the word receptor at the end. Their
number is smallest for the BioNLP data at 3% but larger for
the Texas and Yapex datasets at 17.3% and 17.6%, respec-
tively.
All previous examples examined right boundaries of pro-
tein names. Left boundaries of protein names vary equally
across datasets particularly with regard to the decision of
whether to consider an organism preceding a protein name
as part of the entity or not. Organisms are mostly included
in the protein name in the annotation of the BioNLP and
the PIR data as in the following example:
(6) . . .   prot  human CD14   /prot  . . .
Nevertheless, we found a small number of inconsistencies
in both datasets. The Texas and the Yapex annotations do
not in the majority of cases include the organism in the pro-
tein entity even if it is specied as part of the protein name
indicated by an abbreviation or acronym, e.g.:
(7) . . . human   prot  leukocyte antigen   /prot 
(   prot  HLA   /prot  ) . . .
Similarly, organisms are also not annotated as part of the
protein name in the Bio1 data but as a multi-cell source
entity preceding a protein entity.
4.2. Coordinated Protein Named Entities
Regarding coordination of type X and/or Y proteins, the
actual protein names X and Y are annotated as two sepa-
rate entities in the Texas and the Yapex datasets, e.g. see
Example (8) taken from the Texas data:
(8) . . .   prot  Rad51   /prot  or
  prot  Rad52   /prot  proteins . . .
The annotation of this type of coordinated NP differs in all
other collections. There the word proteins which modies
all coordinated members of the NP is annotated as part of
the last protein name, e.g. see Example (9) taken from the
PIR data:
(9) . . .   prot  hRad54   /prot  and   prot  hRad54B
proteins   /prot  . . .
In the BioNLP test data we also detected a number of cases
where the entire coordinated NP with all protein members
was annotated as one protein name entity.
4.3. Abbreviations and Acronyms
In the PIR data, a protein name abbreviation is only an-
notated as a separate entity in case it precedes additional
information in the brackets. Generally, full protein names
and their abbreviations or acronyms which co-occur in the
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text in either order are marked up as one entity in this col-
lection, e.g.:
(10) . . .   prot  ATR (anthrax toxin receptor)   /prot 
. . .
(11) . . .   prot  transforming growth factor alpha
(TGF-alpha)   /prot  . . .
In all the other datasets, full names as well as abbrevia-
tions and acronyms are mostly considered as separate pro-
tein names unless they are part of a larger protein name.
So for example, the string interleukin 2 (IL-2) contains the
protein names interleukin 2 and IL-2 as shown in Exam-
ple (12).
(12) . . .   prot  interleukin 2   /prot  (   prot  IL-2
  /prot  ) . . .
We have found some inconsistencies within several of the
data sets. For example, the string interleukin 2 (IL-2) in
Example (12) taken from the Bio1 corpus also occurs in the
same collection annotated as one protein name in a similar
fashion to in the PIR data.
4.4. General Protein Names
Proteins are also frequently described in more general
terms, such as cellular protein, regulatory protein or inte-
gral membrane protein. These general expressions are de-
liberately annotated as entities in the BioNLP and the PIR
datasets. Conversely, they are not considered as protein en-
tities in the other datasets. For example the string integral
membrane protein is marked up completely differently in
the BioNLP and the Yapex data (see Examples (13) and
(14), respectively).
(13) . . .   prot  integral membrane protein   /prot  . . .
(14) . . . integral membrane protein . . .
In the BioNLP and the PIR data, such general protein de-
scriptions are even annotated if they refer to more than one
specic protein, e.g. regulatory proteins. It becomes clear
that the annotators working on those two corpora had or
were provided with a very different concept of what consti-
tutes a named entity compared to those employed to mark
up the other data sets.
5. Discussion and Conclusion
We discussed a series of inconsistencies that exist across
and even within different datasets which cause boundary er-
rors and increase the number of false positives. This means
that increasing the size of the training data by adding new
annotated data is never benecial unless the annotations of
individual collections happen to be similar enough. Even
then, inconsistencies within a dataset are detrimental to the
tagger’s performance. Considering the increasing amount
of work dedicated to information extraction from biomed-
ical publications, we believe that the creation of standard
annotation guidelines for various entities of interest will not
only improve recognition performance but also encourage
the shareability of resources (see also Cohen et al. (2005a)
on features that make a corpus useful). The experiments
we have presented have singled out specic annotation is-
sues that we believe should receive priority attention in any
new annotation project. When comparing the various anno-
tation schemes of all the biomedical corpora we have also
observed slight differences in the denition of specic en-
tity types. We believe that future efforts in biomedical cor-
pus annotation will become more attractive if they follow
the standardised denitions and guidelines.
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